All In Biotech

Drug Trial Radar · NCT01127620

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-term Safety Extension With Bilastine 20 mg

Last checked: Nov 20, 2026Latest source record: Sep 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

650

Actual

Start

May 2004

Primary completion

Mar 2006

Study completion Nov 2006

Sponsor

Lead sponsor
Faes Farma, S.A.Industry
Sponsor type
Industry
First posted
May 21, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Double-blind phase: The objective of the study was to evaluate the efficacy and safety of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of perennial allergic rhinitis. Open-label Phase: The objective of this extension was to evaluate the long-term safety of Bilastine 20 mg during one year in the symptomatic treatment of perennial allergic rhinitis

Conditions

  • Perennial Allergic Rhinitis

Interventions

  • BilastineDrug

    20 mg encapsulated tablets

  • CetirizineDrug

    10 mg encapsulated tablets

  • PlaceboDrug

    encapsulated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-blind phase: AUC of TSS throughout the studyTime frame: 28 days
  2. Open-label phase: Long-term safetyTime frame: 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.